REZAFUNGIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C63H85N8O17
Molecular Weight	1226.3924
Optical Activity	UNSPECIFIED
Defined Stereocenters	15 / 15
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@H](NC(=O)[C@]3([H])[C@@H](O)[C@@H](C)CN3C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@@H](C)O)OCC[N+](C)(C)C)NC(=O)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=C(OCCCCC)C=C7)[C@@H](C)O

InChI

InChIKey=LNFCWEXGZIEGJW-TXSVMFMRSA-O

InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.cidara.com/wp-content/uploads/2014/12/A-694.-Biafungin-CD101-a-Novel-Echinocandin-Displays-a-Long-Half-life-in-the-Chimpanzee-Suggesting-a-Once-Weekly-IV-Dosing-Option.pdf | https://clinicaltrials.gov/ct2/show/NCT02733432 | https://www.ncbi.nlm.nih.gov/pubmed/29307565

Biafungin (formerly SP 3025 or CD101), a highly stable echinocandin and an antifungal drug that was studied against panels of Candida and Aspergillus clinical isolates. Biafungin was involved in phase II clinical trials in the treatment of acute moderate to severe vulvovaginal candidiasis. Seachaid Pharmaceuticals invented this drug. Then Cidara Therapeutics acquired a worldwide exclusive license to develop and commercialize the drug.

Originator

Approval Year

PubMed

Title	Date	PubMed
CD101: a novel long-acting echinocandin.	2016 Sep	27354115
Systemic Antifungal Agents: Current Status and Projected Future Developments.	2017	27837500
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris.	2018 Mar	29307565

Sample Use Guides

In Vivo Use Guide

CD101 (Biafungin) Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2. CD101 external gel (1%) applied topically twice daily over 72 hours as needed

Route of Administration: Vaginal

Name

Type

Language

REZAFUNGIN

Official Name

English

CD101

Code

English

BIAFUNGIN

Common Name

English

CD-101

Code

English

REZAFUNGIN [USAN]

Common Name

English

2-(((2R,6S,9S,11R,12R,14AS,15S,16S,20S,23S,25AS)-23-((1S,2S)-1,2-DIHYDROXY-2-(4-HYDROXYPHENY)ETHYL)-2,11,15-TETRAHYDROXY-6,20-BIS((1R)-1-HYDROXYETHYL)-16-METHYL-5,8,14,19,22,25-HEXAOXO-9-(34-(PENTYLOXY)-11,21:24,31-TERPHENYL-14-CARBOXAMIDO)TETRACOSAHYDRO

Systematic Name

English

ECHINOCANDIN B, 1-((4R,5R)-4-HYDROXY-N2-((4''-(PENTYLOXY)(1,1':4',1''-TERPHENYL)-4-YL)CARBONYL)-5-(2-(TRIMETHYLAMMONIO)ETHOXY)-L-ORNITHINE)-4-((4S)-4-HYDROXY-4-(4-HYDROXYPHENYL)-L-ALLOTHREONINE)-

Systematic Name

English

REZAFUNGIN CATION

Common Name

English

SP-3025

Code

English

REZAFUNGIN ION

Common Name

English

Rezafungin [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C514